CRIO, a leading eSource provider, has received a substantial investment from The Riverside Company. This investment will enable CRIO to enhance its eClinical platform, offering more value to clinical research sites, biopharmaceutical companies, and CROs. CRIO's platform integrates various clinical trial management systems that streamline research at the site level, reduce costs, increase trial speed, and improve data quality. The investment will empower CRIO to expand its capabilities, introduce new functionalities, and transform clinical trial data capture and management. With the support of The Riverside Company's industry expertise, CRIO's mission to optimize clinical trials for quality, speed, and patient-centricity will continue to be fulfilled. Ultimately, this investment will make life-changing therapies more accessible to patients. Check out the details of the investment here: https://lnkd.in/dsY9WGi2
Marc Wartenberger Raymond Nomizu
Congrats 👏👏👏